Management of Locally Advanced and Metastatic HER2—Positive Breast Cancer

Phoenix, AZ US
November 8, 2015

Learning Objectives

  • Describe scientific updates and key practice changes in the management of advanced HER2-positive breast cancer
  • Review HER2 testing guidelines for patients with breast cancer
  • Discuss best sequencing of FDA approved targeted agents, mechanism of action and toxicities
  • Explain the role of neoadjuvant chemotherapy in HER2-positive breast cancer, including use of HER2-targeted agents
  • Describe collaboration between various members of the healthcare team (including but not limited to physician, advanced practitioner, and pharmacist) in management strategies for patients with advanced HER2 positive breast cancer
Course summary
Available credit: 
  • 1.00 AANP
  • 0.75 Pharmacology
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC
Course opens: 
11/08/2015
Course expires: 
03/31/2016
Event starts: 
11/08/2015 - 9:00am
Event ends: 
11/08/2015 - 10:00am
Cost:
$0.00
Parent activity set: 
Rating: 
0
JW Marriott Desert Ridge
5350 East Marriott Drive
Phoenix, AZ 85054
United States

Melanie E. Royce, MD, PhD
Karen Herold, DNP, FNPOBC, WHCNP-BC

Available Credit

  • 1.00 AANP
  • 0.75 Pharmacology
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC

Price

Cost:
$0.00
Please login or register to take this course.